Skip to Content

Onivyde Approval History

  • FDA approved: Yes (First approved October 22nd, 2015)
  • Brand name: Onivyde
  • Generic name: irinotecan liposomal
  • Dosage form: Injection
  • Previous name: MM-398
  • Company: Merrimack Pharmaceuticals, Inc.
  • Treatment for: Pancreatic Cancer

Onivyde (irinotecan liposome injection) is a liposomal formulation of the topoisomerase I inhibitor irinotecan indicated for the treatment of post-gemcitabine metastatic adenocarcinoma of the pancreas.

Development History and FDA Approval Process for Onivyde

DateArticle
Oct 22, 2015Approval FDA Approves Onivyde (irinotecan liposome injection) for Advanced Pancreatic Cancer
Jun 25, 2015U.S. FDA Grants Priority Review for MM-398 New Drug Application
Apr 27, 2015Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of NDA Submission for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide